Researchers at the University of Rochester School of Medicine are using a special breed of frogs to study human diseases such as cancer. It turns out our amphibious friends have a lot to teach us about how tumors grow.Read More
Science Market Update
In 1962, John F. Kennedy declared that the United States would go to the moon and in 1969, we did. Now President Obama is calling for the same level of national focus and dedication to win the war against cancer. He announced a new “moonshot” during his last State of the Union Address - a moonshot to cure cancer.Read More
Cervical cancer is the third leading cause of cancer deaths for women worldwide, with more than 500,000 new cases per year. In the United States, however, early screening and HPV vaccine have resulted in a decline in U.S. rates to approximately 12,000 cases annually.Read More
Tags: University of Wisconsin Madison Research Park, cancer research, Wisconsin, UWiscRP, UWisc, Cancer, UW Madison, 2015, BioResearch Product Faire Front Line Event, BioResearch Product Faire Event, Madison
According to the National Cancer Institute (NCI), ovarian cancer accounts for approximately 3 percent of all cancers in women and is the fifth leading cause of cancer-related death among women in the United States. Ovarian cancer causes more deaths than any other female reproductive system cancer, due in part to a lack of symptoms during early stages and a lack of effective screening tests. In 2014, for example, an estimated 22,000 women were diagnosed with ovarian cancer in the United States, and approximately 14,000 died of the disease.Read More
Tags: CA, University of California San Diego, cancer research, California, Cancer Treatment, Cancer, 2015, San Diego, SDVS, UCSD, Research Funding, UC San Diego, Biotechnology Vendor Showcase, NIH grants, ovarian cancer
Pancreatic cancer is one of the most rapidly spreading cancers known to man, which translates to seriously staggering death rates. According to the American Cancer Society, for all stages of pancreatic cancer combined, the one-year relative survival rate is 20%, and the five-year rate is 6%, in part because more than 80% of patient tumors have spread beyond the pancreas by the time of diagnosis. In most cases, the cancer has already spread to the point where surgical removal is impossible. (Image: Test Molecule; Los Angeles Mission College)Read More
Georgetown University has recently received funding from the National Institutes of Health in order to advance cancer research, including breakthrough research on cancer cells' behavior and the "Hippo" pathway at the Georgetown Lombardi Comprehensive Cancer Center.Read More
No one escapes being affected by cancer. We all know someone, perhaps even a family member who has been diagnosed with cancer. According to the National Cancer Institute, more than 1.6 million people will be diagnosed with cancer in 2012. In fact, it is estimated that each person has a 41% chance of developing cancer during his or her lifetime. But new discoveries by researchers have started to change the outcome of a cancer diagnosis. In a recently published article in Nature, two researchers at CU boulder have found a possible solution hiding at the ends of our DNA. According to Professor Cech, "This is an exciting scientific discovery that gives us a new way of looking at the problem of cancer.” The researchers, Tom Cech and Leslie Leinwand, found the solution by studying how telomerase functions in our cells. In normal people, telomerase helps us keep our cells healthy and young.
At the Wyss Institute for Biologically Inspired Engineering at Harvard University, in the Longwood medical neighborhood in Boston, researchers have reached a biotech milestone with tremendous potential for future drug testing and development. Instead of resorting to animals for testing, they may soon be using a simulated organ that lives on a chip. It has mechanical and biological (cellular) parts, and yes, it breathes, thanks to a vacuum system that pumps air through. The bio-inspired micro-device has gone through several tests recently to assess its accuracy in mimicking the human lung when bacteria or potentially toxic drugs are introduced. Results: Positive. The lung-on-a-chip replicates responses found in animal models and observations of human lung function. Indeed, because the device uses human lung and blood vessel cells, it acts may act more like a lung in a human body than lab animals.
Tags: Northeast, Lab-on-a-chip Technology, 2012, Massachusetts, Cancer, biological, Boston, BioResearch Product Faire Event, MA, Harvard, innovative solutions, Drug Development, Harvard Medical School, bio medical research
Often growing up as a child you hear, “eat your veggies if you want to grow up to be big and strong.” With new research on triple negative breast cancer, that old saying might have to change to "eat your veggies if you want to keep cancer away". Recently, at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Mandip Sachdeva announced: "We are confident that the compounds we are currently working with are an effective treatment for triple-negative breast cancer. These compounds are safer for the patient than current treatments available".
Tags: Bioscience research, cancer research, Texas A&M University, Texas, 2012, Cancer Treatment, Cancer, College Station, BioResearch Product Faire Event, Texas A&M Research, Texas A&M Life Science Funding, TX, Texas A&M
Cancer research is hot, and the best in the field are hotly-courted by top cancer research centers, often with very attractive compensation packages in addition to state-of-the-art labs and equipment. As if fighting cancer weren't challenging enough, even renowned universities with world-class biomedical programs like the University of California San Diego have had some of their shining stars in the laboratory snatched away by big-money states like Texas in recent years. Not to be outdone or undermined, UCSD has recently engaged in some aggressive recruiting of its own and is proud to announce that two very important players in the cancer research field have joined the Moores Cancer Center faculty: Dr. Napoleone Ferrara (formerly of Genentech) and Dr. Razelle Kurzrock (formerly of MD Anderson at the University of Texas).